Differences in sensitivity to new therapies between primary and metastatic breast cancer: A need to stratify the tumor response?

OBJECTIVE: We compared therapeutic response of Varlitinib + Capecitabine (VC) versus Lapatinib + Capecitabine (LC) in patients with human epidermal growth factor receptor 2‐positive metastatic breast cancer after trastuzumab therapy by assessing changes in target lesion (TL) diameter and volume per...

Descripción completa

Detalles Bibliográficos
Autores principales: Beaumont, Hubert, Faye, Nathalie, Iannessi, Antoine, Chamorey, Emmanuel, Klifa, Catherine, Hsieh, Chih‐Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939226/
https://www.ncbi.nlm.nih.gov/pubmed/36098367
http://dx.doi.org/10.1002/cam4.5236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939226/
https://www.ncbi.nlm.nih.gov/pubmed/36098367
http://dx.doi.org/10.1002/cam4.5236

Ejemplares similares